Short Interest in Immunome, Inc. (NASDAQ:IMNM) Rises By 9.3%

Immunome, Inc. (NASDAQ:IMNM – Get Rating) was the target of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 145,800 shares, an increase of 9.3% from the February 13th total of 133,400 shares. Currently, 1.5% of the company’s shares are sold short. Based on an average trading volume of 86,200 shares, the short-interest ratio is presently 1.7 days.

Hedge Funds Weigh In On Immunome

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Immunome by 0.8% during the third quarter. Vanguard Group Inc. now owns 373,685 shares of the company’s stock worth $1,659,000 after buying an additional 3,149 shares during the last quarter. First Republic Investment Management Inc. acquired a new stake in shares of Immunome during the first quarter worth about $87,000. Renaissance Technologies LLC acquired a new stake in shares of Immunome during the first quarter worth about $80,000. UBS Group AG raised its position in shares of Immunome by 1,049.9% during the third quarter. UBS Group AG now owns 15,271 shares of the company’s stock worth $68,000 after purchasing an additional 13,943 shares during the period. Finally, Natixis acquired a new stake in shares of Immunome during the fourth quarter worth about $25,000. Institutional investors own 19.74% of the company’s stock.

Immunome Trading Up 9.2 %

Shares of IMNM opened at $5.15 on Friday. Immunome has a 1 year low of $2.09 and a 1 year high of $6.40. The stock has a market cap of $62.41 million, a P/E ratio of -1.65 and a beta of 1.74. The stock’s 50-day moving average price is $4.87 and its two-hundred day moving average price is $4.47.

Analyst Upgrades and Downgrades

Separately, Chardan Capital reduced their target price on Immunome from $9.00 to $8.00 in a report on Thursday.

About Immunome

(Get Rating)

Immunome, Inc, a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.